News

Morcellation shows favorable risk/benefit ratio in decision analysis

Publish date: September 23, 2014

 

AT MINIMALLY INVASIVE SURGERY WEEK

References

Dr. Siedhoff reported having no financial conflicts regarding the decision analysis, conducted with university funds.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

FDA panel recommends informed consent, labeling changes to address morcellator risk
MDedge ObGyn
Study provides cancer risk estimates among women undergoing morcellation
MDedge ObGyn
Study provides cancer risk estimates among women undergoing morcellation
MDedge ObGyn
New ACOG opinions address gynecologic concerns in young cancer patients
MDedge ObGyn
Key ways to differentiate a benign from a malignant adnexal mass
MDedge ObGyn
Fertility treatment was associated with limited cancer risks
MDedge ObGyn
Ethicon pulls morcellators off the market, citing ‘uncertain’ risk-benefit
MDedge ObGyn
Surgery in an aging population, part 2
MDedge ObGyn
No unexpected leiomyosarcomas in chart review of TVH and LAVH cases
MDedge ObGyn
Risk factors identified for occult cancers found at risk-reducing salpingo-oophorectomy
MDedge ObGyn